{"entity":{"id":"adi-270","kind":"drug","name":"ADI-270","aka":[],"tldr":"ADI-270 is an experimental CAR-T cell therapy from Adicet Therapeutics in phase 2 trials for renal cell carcinoma, aimed at CD70.","summary":"ADI-270 is a CAR-T cell therapy developed by Adicet Therapeutics. Its target is CD70 (the sponsor names CD70). The sponsor states: An armoured, allogeneic 'off-the-shelf' CAR gamma-delta (CAR-γδ) T-cell therapy directed against CD70-expressing cells, with reported CAR-directed and CAR-independent anti-tumour activity against solid and haematologic malignancies. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in renal cell carcinoma. The largest, NCT06480565, plans to enrol 60 participants with primary completion expected 2026-12. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of ADI-270","url":"https://clinicaltrials.gov/search?intr=ADI-270"},{"label":"Sponsor pipeline page","url":"https://adicetbio.com/pipeline"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["rcc"],"sections":[],"technologies":[],"targets":["cd70"],"drugs":[],"companies":["adicet-bio"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06480565"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"CAR-T cell therapy","mechanism":"An armoured, allogeneic 'off-the-shelf' CAR gamma-delta (CAR-γδ) T-cell therapy directed against CD70-expressing cells, with reported CAR-directed and CAR-independent anti-tumour activity against solid and haematologic malignancies.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/adi-270/","neighbours":{"cancer":[{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"target":[{"id":"cd70","kind":"target","name":"CD70","route":"/targets/cd70/"}],"company":[{"id":"adicet-bio","kind":"company","name":"Adicet Bio","route":"/companies/adicet-bio/"}],"trial":[{"id":"nct06480565","kind":"trial","name":"A Phase 1/2 Trial of ADI-270 in ccRCC","route":"/trials/nct06480565/"}]}}